Clinical Trial

Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute Myeloblastic Leukemia

Study acronym: EUREKA-VEN
Recruiting
View on ClinicalTrials.gov →
Summary
This is a prospective, multicenter, clinical-biological cohort study. Its objective is to assess the pharmacokinetics-pharmacodynamics (PK-PD) of venetoclax (VEN) in patients with Acute Myeloid Leukemia (AML). This study involves only minimal risks and constraints related to the collection of biological samples (blood samples for PK testing) and the collection of clinical data. Therapeutic management of patients participating in this study is not changed. A total of 100 patients will be included in the study over a 12-month period. A maximum of 21 additional samples are planned, with a maximum of 12 mL of blood per sampling day (4 mL at each sampling time) for PK dosing of venetoclax.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-11-17; most recent amendment 2026-05-07.
Status change: Not Yet Recruiting → Recruiting 2025-12-11
Trial Details
NCT Number NCT07243483
Lead Sponsor Centre Leon Berard
Collaborators: Fédération Leucémie Espoir
Conditions Acute Myeloid Leukemia
Enrollment 100 participants
Start Date 2026-01-21
Primary Completion 2028-01-01 (estimated)
Study Completion 2029-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-08